## Daniel M Moreira

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9344178/publications.pdf

Version: 2024-02-01

150 papers 4,576 citations

94433 37 h-index 61 g-index

153 all docs

153
docs citations

153 times ranked

5622 citing authors

#	Article	IF	CITATIONS
1	The impact of smoking on sexual function. BJU International, 2022, 130, 186-192.	2.5	4
2	Prostate Cancer Disparities in Hispanics Using the National Cancer Database. Urology, 2022, 165, 218-226.	1.0	2
3	The association of cancer-specific anxiety with disease aggressiveness in men on active surveillance of prostate cancer. Prostate Cancer and Prostatic Diseases, 2021, 24, 335-340.	3.9	13
4	Chronic Baseline Prostate Inflammation is Associated with Lower Tumor Grade in Men with Prostate Cancer on Repeat Biopsy: Results from the REDUCE Study. Journal of Urology, 2021, 205, 755-760.	0.4	2
5	Smoking Is Associated With Basal Cell Hyperplasia on Prostate Biopsy Specimens. American Journal of Clinical Pathology, 2021, 156, 934-938.	0.7	O
6	Association between environmental quality and prostate cancer stage at diagnosis. Prostate Cancer and Prostatic Diseases, 2021, 24, 1129-1136.	3.9	9
7	Dutasteride Improves Nocturia but Does Not Lead to Better Sleep: Results from the REDUCE Clinical Trial. Journal of Urology, 2021, 205, 1733-1739.	0.4	5
8	Helping Men Find Their Way: Improving Prostate Cancer Clinic Attendance via Patient Navigation. Journal of Community Health, 2020, 45, 561-568.	3.8	4
9	Diagnostic Properties of Total and Free Prostate-Specific Antigen to Predict Overall and Clinically Significant Prostate Cancer Among Men With Low Testosterone and Prior Negative Biopsy. Urology, 2020, 137, 97-101.	1.0	4
10	Statin use and longitudinal changes in prostate volume; results from the REduction by DUtasteride of prostate Cancer Events ( <scp>REDUCE)</scp> trial. BJU International, 2020, 125, 226-233.	2.5	5
11	Sleep quality and prostate cancer aggressiveness: Results from the REDUCE trial. Prostate, 2020, 80, 1304-1313.	2.3	8
12	Both acute and chronic inflammation are associated with less perineural invasion in men with prostate cancer on repeat biopsy. BJU International, 2019, 123, 91-97.	2.5	11
13	Implementation of multiparametric magnetic resonance imaging technology for evaluation of patients with suspicion for prostate cancer in the clinical practice setting. BJU International, 2019, 123, 239-245.	2.5	5
14	Fosfomycin trometamol vs ciprofloxacin for antibiotic prophylaxis before transrectal ultrasonography-guided prostate biopsy: A meta-analysis of clinical studies. Arab Journal of Urology Arab Association of Urology, 2019, 17, 114-119.	1.5	16
15	Left Kidney Within a Large Left Inguinal Hernia. Urology, 2019, 128, 5-7.	1.0	3
16	Nocturia and associated mortality: observational data from the REDUCE trial. Prostate Cancer and Prostatic Diseases, 2019, 22, 77-83.	3.9	14
17	Constructing and Pilot Testing a Novel Prostate Magnetic Resonance Imaging/Ultrasound Fusion Biopsy Phantom. Urology, 2019, 124, 33-37.	1.0	6
18	Prostate cancer disparities in Hispanics by country of origin: a nationwide population-based analysis. Prostate Cancer and Prostatic Diseases, 2019, 22, 159-167.	3.9	17

#	Article	IF	CITATIONS
19	Geographic Differences in Baseline Prostate Inflammation and Relationship with Subsequent Prostate Cancer Risk: Results from the Multinational REDUCE Trial. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 783-789.	2.5	1
20	Inflammation on Prostate Needle Biopsy is Associated with Lower Prostate Cancer Risk: A Meta-Analysis. Journal of Urology, 2018, 199, 1174-1181.	0.4	31
21	Serum cholesterol and risk of high-grade prostate cancer: results from the REDUCE study. Prostate Cancer and Prostatic Diseases, 2018, 21, 252-259.	3.9	71
22	Determinants of Clinic Absenteeism: A Novel Method of Examining Distance from Clinic and Transportation. Journal of Community Health, 2018, 43, 19-26.	3.8	14
23	Sleep Problems are Associated with Development and Progression of Lower Urinary Tract Symptoms: Results from REDUCE. Journal of Urology, 2018, 199, 536-542.	0.4	19
24	Baseline prostate atrophy is associated with lower tumor volume in men with prostate cancer on repeat biopsy. Prostate Cancer and Prostatic Diseases, 2018, 21, 106-112.	3.9	2
25	Perioperative Morbidity of Lymph Node Dissection for Renal Cell Carcinoma: A Propensity Score–based Analysis. European Urology, 2018, 73, 469-475.	1.9	10
26	The Association of Previous Prostate Biopsy Related Complications and the Type of Complication with Patient Compliance with Rebiopsy Scheme. Journal of Urology, 2018, 200, 1062-1067.	0.4	1
27	PSA predicts development of incident lower urinary tract symptoms: results from the REDUCE study. Prostate Cancer and Prostatic Diseases, 2018, 21, 238-244.	3.9	12
28	The association of lymph node dissection with 30-day perioperative morbidity among men undergoing minimally invasive radical prostatectomy: analysis of the National Surgical Quality Improvement Program (NSQIP). Prostate Cancer and Prostatic Diseases, 2018, 21, 245-251.	3.9	6
29	Impact of Prostate-specific Antigen (PSA) Screening Trials and Revised PSA Screening Guidelines on Rates of Prostate Biopsy and Postbiopsy Complications. European Urology, 2017, 71, 55-65.	1.9	43
30	Chronic Prostate Inflammation Predicts Symptom Progression in Patients with Chronic Prostatitis/Chronic Pelvic Pain. Journal of Urology, 2017, 198, 122-128.	0.4	43
31	Serum cholesterol and risk of lower urinary tract symptoms progression: Results from the Reduction by Dutasteride of Prostate Cancer Events study. International Journal of Urology, 2017, 24, 151-156.	1.0	8
32	Renal Cell Carcinoma with Isolated Lymph Node Involvement: Long-term Natural History and Predictors of Oncologic Outcomes Following Surgical Resection. European Urology, 2017, 72, 300-306.	1.9	69
33	Redefining and Contextualizing the Hospital Volume-Outcome Relationship for Robot-Assisted Radical Prostatectomy: Implications for Centralization of Care. Journal of Urology, 2017, 198, 92-99.	0.4	55
34	Partial Nephrectomy is Associated with Higher Risk of Relapse Compared with Radical Nephrectomy for Clinical Stage T1 Renal Cell Carcinoma Pathologically Up Staged to T3a. Journal of Urology, 2017, 198, 289-296.	0.4	58
35	Does Peak Urine Flow Rate Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from REDUCE. Journal of Urology, 2017, 198, 650-656.	0.4	3
36	Statin Use, Serum Lipids, and Prostate Inflammation in Men with a Negative Prostate Biopsy: Results from the REDUCE Trial. Cancer Prevention Research, 2017, 10, 319-326.	1.5	23

#	Article	IF	CITATIONS
37	Thresholds for <scp>PSA</scp> doubling time in men with nonâ€metastatic castrationâ€resistant prostate cancer. BJU International, 2017, 120, E80-E86.	2.5	46
38	Extent of Baseline Prostate Atrophy Is Associated With Lower Incidence of Low- and High-grade Prostate Cancer on Repeat Biopsy. Urology, 2017, 103, 161-166.	1.0	10
39	Association of Obesityâ€Related Hemodilution of Prostateâ€Specific Antigen, Dihydrotestosterone, and Testosterone. Prostate, 2017, 77, 466-470.	2.3	25
40	Timing of Prostate-specific Antigen Nadir After Radical Prostatectomy and Risk of Biochemical Recurrence. Urology, 2017, 108, 129-134.	1.0	17
41	Predictors of operative time during radical retropubic prostatectomy and robotâ€assisted laparoscopic prostatectomy. International Journal of Urology, 2017, 24, 618-623.	1.0	16
42	Biopsy Detected Gleason Pattern 5 is Associated with Recurrence, Metastasis and Mortality in a Cohort of Men with High Risk Prostate Cancer. Journal of Urology, 2017, 198, 1309-1315.	0.4	15
43	Dutasteride is associated with reduced risk of transrectal prostate biopsy-associated urinary tract infection and related hospitalizations. World Journal of Urology, 2017, 35, 1525-1530.	2.2	1
44	Active surveillance for incidental renal mass in the octogenarian. World Journal of Urology, 2017, 35, 1089-1094.	2.2	12
45	Predictors of Complications After Percutaneous Image-Guided Renal Cryoablation for T1a Renal Cortical Neoplasms. Journal of Endourology, 2017, 31, 7-13.	2.1	13
46	Lymph Node Dissection is Not Associated with Improved Survival among Patients Undergoing Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: A Propensity Score Based Analysis. Journal of Urology, 2017, 197, 574-579.	0.4	41
47	Radical Nephrectomy With or Without Lymph Node Dissection for Nonmetastatic Renal Cell Carcinoma: A Propensity Score-based Analysis. European Urology, 2017, 71, 560-567.	1.9	58
48	Predicting Time From Metastasis to Overall Survival in Castration-Resistant Prostate Cancer: Results From SEARCH. Clinical Genitourinary Cancer, 2017, 15, 60-66.e2.	1.9	79
49	Identification of Site-specific Recurrence Following Primary Radiation Therapy for Prostate Cancer Using C-11 Choline Positron Emission Tomography/Computed Tomography: A Nomogram for Predicting Extrapelvic Disease. European Urology, 2017, 71, 340-348.	1.9	51
50	Racial differences in prostate inflammation: results from the REDUCE study. Oncotarget, 2017, 8, 71393-71399.	1.8	10
51	Evaluation of <scp>pT</scp> 0 prostate cancer in patients undergoing radical prostatectomy. BJU International, 2016, 118, 379-383.	2.5	7
52	Radiographic size of retroperitoneal lymph nodes predicts pathological nodal involvement for patients with renal cell carcinoma: development of a risk prediction model. BJU International, 2016, 118, 742-749.	2.5	32
53	Validation of a bone scan positivity risk table in nonâ€metastatic castrationâ€resistant prostate cancer. BJU International, 2016, 118, 570-577.	2.5	8
54	Chronic Prostate Inflammation is Associated with Severity and Progression of Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms and Risk of Acute Urinary Retention. Journal of Urology, 2016, 196, 1493-1498.	0.4	59

#	Article	IF	CITATIONS
55	To clamp or not to clamp? Longâ€term functional outcomes for elective offâ€clamp laparoscopic partial nephrectomy. BJU International, 2016, 117, 293-299.	2.5	37
56	Salvage Percutaneous Cryoablation for Locally Recurrent Renal-Cell Carcinoma After Primary Cryoablation. Journal of Endourology, 2016, 30, 632-637.	2.1	27
57	The Association between Phosphodiesterase Type 5 Inhibitors and Prostate Cancer: Results from the REDUCE Study. Journal of Urology, 2016, 196, 715-720.	0.4	11
58	Positive Surgical Margins Increase Risk of Recurrence after Partial Nephrectomy for High Risk Renal Tumors. Journal of Urology, 2016, 196, 327-334.	0.4	136
59	Does Prostate Size Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from the REDUCE Trial. European Urology, 2016, 69, 885-891.	1.9	26
60	Paraneoplastic syndromes are associated with adverse prognosis among patients with renal cell carcinoma undergoing nephrectomy. World Journal of Urology, 2016, 34, 1465-1472.	2.2	19
61	Predictors of Time to Metastasis in Castration-resistant Prostate Cancer. Urology, 2016, 96, 171-176.	1.0	55
62	Outcomes of Laparoscopic Partial Nephrectomy in Patients Continuing Aspirin Therapy. Journal of Urology, 2016, 195, 859-864.	0.4	16
63	The association of ABO blood type with disease recurrence and mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 4.e1-4.e9.	1.6	19
64	Association of estimated glomerular filtration rate with 24-h urinalysis and stone composition. Urolithiasis, 2016, 44, 319-325.	2.0	7
65	Comprehensive Characterization of the Perioperative Morbidity of Cytoreductive Nephrectomy. European Urology, 2016, 69, 84-91.	1.9	47
66	Metabolic syndromeâ€like components and prostate cancer risk: results from the Reduction by Dutasteride of Prostate Cancer Events ( <scp>REDUCE</scp> ) study. BJU International, 2015, 115, 736-743.	2.5	35
67	Clinicopathologic characteristics and survival for adult renal sarcoma: A population-based study. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 505.e15-505.e20.	1.6	7
68	Chronic baseline prostate inflammation is associated with lower tumor volume in men with prostate cancer on repeat biopsy: Results from the REDUCE study. Prostate, 2015, 75, 1492-1498.	2.3	20
69	Does Obesity Modify the Ability of Prebiopsy Prostate Specific Antigen to Detect Prostate Cancer on Repeat Biopsy? Results from the REDUCE Study. Journal of Urology, 2015, 194, 52-57.	0.4	3
70	Baseline Perineural Invasion is Associated with Shorter Time to Progression in Men with Prostate Cancer Undergoing Active Surveillance: Results from the REDEEM Study. Journal of Urology, 2015, 194, 1258-1263.	0.4	34
71	Association of serum biochemical metabolic panel with stone composition. International Journal of Urology, 2015, 22, 195-199.	1.0	12
72	Smoking Is Associated with Acute and Chronic Prostatic Inflammation: Results from the REDUCE Study. Cancer Prevention Research, 2015, 8, 312-317.	1.5	27

#	Article	IF	CITATIONS
73	Does Hypertension Impact 24-Hour Urine Parameters in Patients With Nephrolithiasis?. Urology, 2015, 85, 539-543.	1.0	15
74	Aspirin, NSAIDs, and Risk of Prostate Cancer: Results from the REDUCE Study. Clinical Cancer Research, 2015, 21, 756-762.	7.0	91
75	Baseline Prostate Atrophy is Associated with Reduced Risk of Prostate Cancer in Men Undergoing Repeat Prostate Biopsy. Journal of Urology, 2015, 194, 1241-1246.	0.4	15
76	Metformin Use and Risk of Prostate Cancer: Results from the REDUCE Study. Cancer Prevention Research, 2015, 8, 1055-1060.	1.5	28
77	Practice Patterns and Predictors of Followup Imaging after a Negative Bone Scan in Men with Castration Resistant Prostate Cancer: Results from the SEARCH Database. Journal of Urology, 2015, 193, 1232-1238.	0.4	11
78	Editorial Comment. Urology, 2015, 86, 995-996.	1.0	0
79	Differences in 24â€h urine composition between nephrolithiasis patients with and without diabetes mellitus. BJU International, 2015, 115, 619-624.	2.5	21
80	Evaluation and Comparison of Urolithiasis Scoring Systems Used in Percutaneous Kidney Stone Surgery. Journal of Urology, 2015, 193, 154-159.	0.4	345
81	Utility of EUS following endoscopic polypectomy of high-risk rectosigmoid lesions. Endoscopic Ultrasound, 2015, 4, 137.	1.5	6
82	Evaluation of post-operative complications and prolonged length of stay following cytoreductive nephrectomy Journal of Clinical Oncology, 2015, 33, 420-420.	1.6	0
83	Predicting bone scan positivity after biochemical recurrence following radical prostatectomy in both hormone-naive men and patients receiving androgen-deprivation therapy: results from the SEARCH database. Prostate Cancer and Prostatic Diseases, 2014, 17, 91-96.	3.9	12
84	Second Prize: Continuing Aspirin Therapy During Percutaneous Nephrolithotomy: Unsafe or Under-Utilized?. Journal of Endourology, 2014, 28, 1399-1403.	2.1	16
85	The surgical spectacle: a survey of urologists viewing live case demonstrations. BJU International, 2014, 113, 674-678.	2.5	18
86	Aggressive Renal Angiomyolipoma of the Lipomatous Variant With Inferior Vena Cava Thrombus: A Case Report and Review of the Literature. Urology Case Reports, 2014, 2, 9-11.	0.3	7
87	Evaluating the Prostate Cancer Prevention Trial High Grade prostate cancer risk calculator in 10 international biopsy cohorts: results from the prostate biopsy collaborative group. World Journal of Urology, 2014, 32, 185-191.	2.2	28
88	Cigarette smoking is associated with an increased risk of biochemical disease recurrence, metastasis, castrationâ€resistant prostate cancer, and mortality after radical prostatectomy. Cancer, 2014, 120, 197-204.	4.1	69
89	A Systematic Review and Meta-analysis of Tobacco Use and Prostate Cancer Mortality and Incidence in Prospective Cohort Studies. European Urology, 2014, 66, 1054-1064.	1.9	156
90	Percutaneous Nephrolithotomy During Uninterrupted Aspirin Therapy in High–cardiovascular Risk Patients: Preliminary Report. Urology, 2014, 84, 1034-1038.	1.0	7

#	Article	IF	Citations
91	Obesity Increases the Risk for High-Grade Prostate Cancer: Results from the REDUCE Study. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2936-2942.	2.5	84
92	Monthly Variations in Urolithiasis Presentations and Their Association with Meteorologic Factors in New York City. Journal of Endourology, 2014, 28, 599-604.	2.1	29
93	Baseline prostate inflammation is associated with a reduced risk of prostate cancer in men undergoing repeat prostate biopsy: Results from the REDUCE study. Cancer, 2014, 120, 190-196.	4.1	65
94	Comparison of the Metabolic Profile of Mixed Calcium Oxalate/Uric Acid Stone Formers to That of Pure Calcium Oxalate and Pure Uric Acid Stone Formers. Urology, 2014, 84, 289-294.	1.0	11
95	Acute Bladder and Small Bowel Perforation as a Complication of Foley Catheterization. Urology, 2014, 83, e5-e6.	1.0	5
96	Use of a Preoperative Checklist Reduces Risk of Penile Prosthesis Infection. Journal of Urology, 2014, 192, 130-135.	0.4	26
97	Age-Related Changes in 24-Hour Urine Composition Must be Considered in the Medical Management of Nephrolithiasis. Journal of Endourology, 2014, 28, 871-876.	2.1	19
98	Contemporary Perspectives on Laparoendoscopic Single-Site Surgery in Urologic Training and Practice. Journal of Endourology, 2013, 27, 727-731.	2.1	11
99	Obesity Is Associated with Increased Prostate Growth and Attenuated Prostate Volume Reduction by Dutasteride. European Urology, 2013, 63, 1115-1121.	1.9	49
100	Differences in 24-Hour Urine Composition Between Apatite and Brushite Stone Formers. Urology, 2013, 82, 768-772.	1.0	7
101	Using 24-Hour Urinalysis to Predict Stone Type. Journal of Urology, 2013, 190, 2106-2111.	0.4	31
102	S.T.O.N.E. Nephrolithometry: Novel Surgical Classification System for Kidney Calculi. Urology, 2013, 81, 1154-1160.	1.0	465
103	Tandem Ureteral Stents for the Decompression of Malignant and Benign Obstructive Uropathy. Journal of Endourology, 2013, 27, 1297-1302.	2.1	30
104	Imageâ€guided percutaneous renal cryoablation: preoperative risk factors for recurrence and complications. BJU International, 2013, 111, E181-5.	2.5	54
105	Statin use and risk of prostate cancer and high-grade prostate cancer: results from the REDUCE study. Prostate Cancer and Prostatic Diseases, 2013, 16, 254-259.	3.9	53
106	High serum folate is associated with reduced biochemical recurrence after radical prostatectomy: Results from the SEARCH Database. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2013, 39, 312-319.	1.5	5
107	Combined use of EUS-guided FNA and immunocytochemical stains discloses metastatic and unusual diseases in the evaluation of mediastinal lymphadenopathy of unknown etiology. Annals of Thoracic Medicine, 2012, 7, 84.	1.8	11
108	Prostate Cancer Risk in Men with Baseline History of Coronary Artery Disease: Results from the REDUCE Study. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 576-581.	2.5	43

#	Article	IF	Citations
109	Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. World Journal of Urology, 2012, 30, 181-187.	2.2	66
110	Serum Testosterone and Dihydrotestosterone and Prostate Cancer Risk in the Placebo Arm of the Reduction by Dutasteride of Prostate Cancer Events Trial. European Urology, 2012, 62, 757-764.	1.9	116
111	159 PROSTATE CANCER RISK IN MEN WITH PROSTATE AND BREAST CANCER FAMILY HISTORY: RESULTS FROM THE REDUCE STUDY. Journal of Urology, 2012, 187, .	0.4	O
112	1931 IS THE ASSOCIATION BETWEEN DUTASTERIDE USE AND PROSTATE CANCER RISK DIFFERENT IN MEN WITH A FAMILY HISTORY OF BREAST OR PROSTATE CANCERS?. Journal of Urology, 2012, 187, .	0.4	0
113	Editorial Comment. Urology, 2012, 79, 1334-1335.	1.0	O
114	Biopsy accuracy in identifying unilateral prostate cancer depends on prostate weight. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 21-25.	1.6	14
115	Editorial Comment. Journal of Urology, 2012, 188, 735-735.	0.4	O
116	R.E.N.A.L. Nephrometry Score Accurately Predicts Complications Following Laparoscopic Renal Cryoablation. Journal of Urology, 2012, 188, 1796-1800.	0.4	37
117	Editorial Comment. Journal of Urology, 2012, 188, 2188-2188.	0.4	O
118	Effect of race and socioeconomic status on surgical margins and biochemical outcomes in an equalâ€access health care setting. Cancer, 2012, 118, 4999-5007.	4.1	49
119	Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group. World Journal of Urology, 2012, 30, 149-155.	2.2	101
120	Prostate cancer risk in men with prostate and breast cancer family history: results from the REDUCE study (R1). Journal of Internal Medicine, 2012, 272, 85-92.	6.0	27
121	Association of prostateâ€specific antigen doubling time and cancer in men undergoing repeat prostate biopsy. International Journal of Urology, 2012, 19, 741-747.	1.0	5
122	Heavy ethanol intake and elevated prostate cancer risk among men with previous negative biopsies in the REDUCE trial Journal of Clinical Oncology, 2012, 30, 187-187.	1.6	0
123	Editorial Comment. Journal of Urology, 2011, 186, 2238-2238.	0.4	O
124	A natural history of weight change in men with prostate cancer on androgenâ€deprivation therapy (ADT): results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU International, 2011, 107, 924-928.	2.5	37
125	The association of diabetes mellitus and high-grade prostate cancer in a multiethnic biopsy series. Cancer Causes and Control, 2011, 22, 977-983.	1.8	47
126	Cigarette Smoking Is Associated With Advanced Renal Cell Carcinoma. Journal of Clinical Oncology, 2011, 29, 2027-2031.	1.6	75

#	Article	IF	CITATIONS
127	Prostate biopsies from black men express higher levels of aggressive disease biomarkers than prostate biopsies from white men. Prostate Cancer and Prostatic Diseases, 2011, 14, 262-265.	3.9	49
128	Predictive value of digital rectal examination for prostate cancer detection is modified by obesity. Prostate Cancer and Prostatic Diseases, 2011, 14, 346-353.	3.9	29
129	Preoperative weight change and risk of adverse outcome following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital database. Prostate Cancer and Prostatic Diseases, 2011, 14, 361-366.	3.9	17
130	On-demand use of erectile aids in men with preoperative erectile dysfunction treated by whole gland prostate cryoablation. International Journal of Impotence Research, 2011, 23, 49-55.	1.8	6
131	Predictors of malignancy in EUS-guided FNA for mediastinal lymphadenopathy in patients without history of lung cancer. Annals of Thoracic Medicine, 2011, 6, 126.	1.8	3
132	Diabetes and prostate cancer risk in the REDUCE trial. Prostate Cancer and Prostatic Diseases, 2011, 14, 326-331.	3.9	52
133	Smoking and prostate cancer survival and recurrence. Asian Journal of Andrology, 2011, 13, 787-788.	1.6	2
134	Predicting Occult Multifocality of Renal Cell Carcinoma. European Urology, 2010, 58, 118-126.	1.9	26
135	Predictors of secondary treatment following biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital database. BJU International, 2010, 105, 28-33.	2.5	21
136	The Shared Equal Access Regional Cancer Hospital (SEARCH) nomogram for risk stratification in intermediate risk group of men with prostate cancer: validation in the Duke Prostate Center database. BJU International, 2010, 105, 180-184.	2.5	6
137	Definition and preoperative predictors of persistently elevated prostateâ€specific antigen after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU International, 2010, 105, 1541-1547.	2.5	20
138	Postoperative prostateâ€specific antigen nadir improves accuracy for predicting biochemical recurrence after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) and Duke Prostate Center databases. International Journal of Urology, 2010, 17, 914-922.	1.0	9
139	The Relationship between Prostate-Specific Antigen and Prostate Cancer Risk: The Prostate Biopsy Collaborative Group. Clinical Cancer Research, 2010, 16, 4374-4381.	7.0	86
140	The effect of race on the discriminatory accuracy of models to predict biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases. Prostate Cancer and Prostatic Diseases, 2010, 13, 87-93.	3.9	13
141	Editorial Comment. Journal of Urology, 2010, 183, 1796-1796.	0.4	3
142	Analysis of Urinary Function Using Validated Instruments and Uroflowmetry After Primary and Salvage Prostate Cryoablation. Urology, 2010, 76, 1258-1265.	1.0	18
143	Association of Cigarette Smoking With Interval to Biochemical Recurrence After Radical Prostatectomy: Results from the SEARCH Database. Urology, 2010, 76, 1218-1223.	1.0	28
144	Validation of a nomogram to predict disease progression following salvage radiotherapy after radical prostatectomy: results from the SEARCH database. BJU International, 2009, 104, 1452-1456.	2.5	38

#	Article	IF	CITATIONS
145	Natural History of Persistently Elevated Prostate Specific Antigen After Radical Prostatectomy: Results From the SEARCH Database. Journal of Urology, 2009, 182, 2250-2256.	0.4	47
146	NATURAL HISTORY OF PERSISTENTLY ELEVATED PSA AFTER RADICAL PROSTATECTOMY: RESULTS FROM THE SEARCH DATABASE. Journal of Urology, 2009, 181, 291-291.	0.4	0
147	PREDICTORS OF CASTRATION RESISTANT PROSTATE CANCER IN MEN UNDERGOING SALVAGE ANDROGEN DEPRIVATION THERAPY - RESULTS FROM THE SEARCH DATABASE. Journal of Urology, 2009, 181, 292-292.	0.4	0
148	THE SHARED EQUAL ACCESS REGIONAL CANCER HOSPITAL (SEARCH) NOMOGRAM FOR RISK STRATIFICATION IN INTERMEDIATE RISK GROUP OF MEN WITH PROSTATE CANCER: VALIDATION IN THE DUKE PROSTATE CENTER (DPC) DATABASE. Journal of Urology, 2009, 181, 272-272.	0.4	0
149	PREDICTORS OF SECONDARY TREATMENT FOLLOWING BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY: RESULTS FROM THE SEARCH DATABASE. Journal of Urology, 2009, 181, 270-271.	0.4	0
150	Recurrent priapism in the young patient treated with baclofen. Journal of Pediatric Urology, 2006, 2, 590-591.	1.1	6